Focused On-demand Library for Eukaryotic translation initiation factor 2 subunit 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P41091

UPID:

IF2G_HUMAN

Alternative names:

Eukaryotic translation initiation factor 2 subunit gamma X

Alternative UPACC:

P41091; A0A024RBY4; A8K2Y2; B2R5N2; B5BTZ4; Q53HK3

Background:

Eukaryotic translation initiation factor 2 subunit 3, also known as Eukaryotic translation initiation factor 2 subunit gamma X, plays a pivotal role in the early steps of protein synthesis. It forms a ternary complex with GTP and initiator tRNA, essential for the formation of the 43S pre-initiation and 80S initiation complexes, crucial for mRNA binding and ribosomal subunit junction.

Therapeutic significance:

Linked to MEHMO syndrome, a condition marked by intellectual disability, seizures, and metabolic anomalies, this protein's genetic variants offer a unique insight into disease mechanisms. Understanding its role could pave the way for innovative therapeutic strategies targeting the underlying genetic causes.